Navigation Links
Eaton Square Expands Biotech Team in US

Eaton Square is pleased to announce its growth on the East Coast of the US with the addition of Popper and Company, a biotechnology and medical technology-focused strategy and M&A advisory firm.

This is an important step for Eaton Square as it continues to grow in the United States, linking US and Asia Pacific healthcare innovators with capital and investors.

Popper and Company, founded in 2003 by Caroline Popper, MD and Ken Walz, helps clients in clinical diagnostics, medical devices, life science tools, and digital health, providing guidance on a variety of commercialization challenges.

The biotechnology and life sciences sector is key to Eaton Square’s continued growth as a cross-border M&A and capital services firm. Given the current global environment, biotechnology is predicted to continue to be extremely active in M&A activity driven by initiatives from large global and regional pharmaceutical companies.

“Eaton Square is focused on assisting clients to grow across the US and internationally. We believe the combination of Popper and Company with our existing Life Sciences and Healthcare capabilities significantly enhances our ability to assist clients in the US and Asia Pacific to undertake transactions and attract capital globally.” Nick Weston, Managing Principal, Eaton Square.

“We are looking forward to initiating global and regional cross-border solutions for pharma, biotech and med-tech sectors. These now include M&A, debt and equity solutions, strategy and advisory. This will give Eaton Square a strong biotech, healthcare, device and A.I. presence in the US and Asia Pacific,” Bob Atwill, Eaton Square Principal.

“At Popper and Company, we are excited to be bringing our deep industry expertise to Eaton Square and we look forward to helping grow the firm’s presence in life sciences and med-tech in the U.S. and globally,” Ken Walz, Eaton Square Principal.

“I am excited to welcome the Popper and Company team to enable us to service more clients looking to grow in the healthcare space. Their presence in the Baltimore/DC area will also strengthen our presence in the East Coast of the United States,” Reece Adnams, Eaton Square CEO.

Joining the Eaton Square Biotech team are:

Ken Walz

Ken Walz has worked for more than 25 years in the biotech, diagnostics, and medical device industries in business development and finance roles and is particularly interested in the application of disruptive technologies to address inefficiencies in the healthcare system. He brings broad experience in commercial operations and strategy development and has extensive experience leading transaction processes. At Popper and Company, he assists clients in all aspects of strategy and corporate development including strategic partnership development, transaction process management, and health economic modeling.

Prior to Popper and Company, Ken held senior positions at MDS Proteomics and Becton Dickinson. Ken holds a BA in Economics from the University of Maryland Baltimore County and an MS in Finance from Loyola College of Maryland.

Caroline Popper, MD

Caroline is a physician with more than 25 years of hands-on operating experience within health care companies. She has managed a wide spectrum of diagnostics, device and drug discovery businesses in both Fortune 500 and start-up settings, at amongst others, Becton Dickinson, bioMerieux, and MDS. She co-founded Popper and Company with Ken Walz specifically to bring integrated strategic and operational expertise to healthcare clients. She earned her medical degree at the University of the Witwatersrand, South Africa and completed post-graduate training in internal medicine and pathologist at Johns Hopkins in Baltimore. She also trained in Health Policy and Health Economics at the Johns Hopkins Bloomberg School of Public Health.

Eaton Square, a cross-border M&A and capital services firm, now has a total of 19 offices across the US, Canada, China & Hong Kong, Australia, New Zealand, UK, Switzerland, Singapore and Israel.

If you would like to arrange a time to speak with our Life Sciences and Healthcare team, please contact them at:
Ken Walz –
Caroline Popper –
Bob Atwill –
Nick Weston –
Reece Adnams –

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology technology :

1. A New Generation of Safe and Reproducible Liquid Distribution From WHEATON®
2. WHEATON® Offers a Turnkey Solution for CHO Cell Bioproduction
3. The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
4. BioMed Realty To Lease 204,900 Square Feet To Life Technologies At The Science Center at Oyster Point In South San Francisco
5. Alexandrias 499 Illinois Street in Mission Bay, San Francisco, Signs Anchor 97,700 Rentable Square Foot Lease with Leading Mid-Cap Life Science Company
6. New 62,600 Square Foot Lease At 650 East Kendall Street Signed By Ipsen And BioMed Realty
7. inMotion’s Latest Website Unveils Innovation Square, Boston’s Premier Life Science Development
8. BioMed Realty Breaks Ground On i3, A New 316,000 Square Foot Iconic Development In San Diego, To Meet The Needs Of The Dynamic Life Science Industry
9. BioMed Realty Forms New Relationship With Stanford Health Care With New 138,000 Square Foot Lease At Pacific Research Center
10. Square Roots Acquires Fitzgerald Analytics, Will Build Data Science + Knowledge Center In Drive To Improve Maternal Health
11. New York Citys First Medical Marijuana Dispensary Opens in Union Square
Post Your Comments:
(Date:7/18/2020)... MILWAUKEE (PRWEB) , ... July 16, 2020 , ... “We ... at Third Wave Bioactives. “It’s the only technology of its kind on the market ... flavor of onions with the protective capacity of traditional cultured ingredients, creating a natural ...
(Date:7/18/2020)... ... July 17, 2020 , ... ... firm for the life sciences and food industries, is pleased to announce that ... Clinical Research – Business Development. , Charles is an accomplished and results-driven sales ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... Technology (MIT) has expanded the company’s exclusive license to include clinical applications ... point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast ...
(Date:7/10/2020)... Mass. (PRWEB) , ... July 09, 2020 , ... ... approaches to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., ... team and oversee the clinical development of Sentien’s lead product, SBI-101. Dr. ...
Breaking Biology Technology:
(Date:8/26/2020)... ... August 25, 2020 , ... ... company developing novel pharmaceuticals targeting mitochondria, in partnership with Essex Bio-Technology, a ... its pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic solution in ...
(Date:8/21/2020)... , ... August 18, 2020 , ... ... cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has ... lead asset, SBI-101, for the treatment of severe COVID-19. Approval of this IND ...
(Date:8/12/2020)... ... August 11, 2020 , ... Both Roche, ... have entered into license agreements with Housey Pharma’s HMI subsidiary to gain access ... J&J have annual Research and Development spending in excess of US $10 billion. ...
Breaking Biology News(10 mins):